

Biovian Unveils the Stonemasonry Work of GeneCity Facility

Press release, 2.11.2023

Biovian, a leading biopharmaceutical CDMO from Finland, uncovers the stonemasonry work of its new manufacturing facility, GeneCity.

Located in a growing technology hub at Turku, Kupittaa, the state-of-the-art facility houses a blend of cutting-edge equipment and technology. The new GeneCity facility, encompassing a total of 6,400 sqm (69,000 sqft), will support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products), such as adenoviral and AAV (adeno-associated viral) therapies along with our current manufacturing facilities. The expansion project is expected to be completed in December 2024, with the new facility fully operational by 2025.

The stonemasonry of GeneCity narrates an important milestone in Biovian's history, representing the dedication to take biopharmaceuticals to the next level. The new facility will stand as a testament of Biovian driving biotechnological progress and creating a physical environment that enables and nurtures innovation. Furthermore, it represents a solid contribution to the expansion of the biopharmaceutical sector in Finland and the endeavor to deliver life-saving treatments to patients suffering from currently incurable diseases.

Antti Nieminen, CEO and co-founder

"The stonemasonry at GeneCity tells a story close to my heart – of scientific progress and growth. This milestone is a good reminder that we are not just building walls but constructing the foundation of our future. GeneCity facility embodies the fusion of our deep-rooted values and the cutting-edge science that drives us to push industry boundaries."

Pirkko Kortteinen, COO and co-founder

"This is an exciting milestone for the company and thus also for our employees. The stonemasonry work and the embedded time capsule signify the personal touch of turning science-based innovations into medicines. This project holds great significance for our team in bringing our services to the world of biotechnology."

To add a unique touch to this milestone, Biovian has embedded a time capsule within the stonemasonry. This time capsule will reflect Biovian's 20th anniversary year and preserve a mosaic poster with photos of our employees, 6 empty injection vials, a filling needle, which is an important part of manufacturing

BIOVIAN

*Contract Development and
Manufacturing of Biopharmaceuticals*

equipment and a template of an analysis request document, creating a bridge between Biovian people and manufacturing practices.

About Biovian

Biovian is a globally operating Contract Development and Manufacturing Organization (CDMO) providing premium services to biotech companies developing innovative gene therapies and biopharmaceuticals. The goal of the company is to turn ideas into products by taking client projects from the laboratory bench to the clinic. With state-of-the-art facilities and a team of dedicated experts, Biovian offers its clients One-Stop-Shop GMP CDMO services, with modularity available from gene to finished vial. Biovian is especially focusing on viral vector production, microbial production of recombinant proteins and GMP plasmid DNA. Guided by its Nordic ethos Biovian has established a reputation for delivering high-quality work on time and within budget to a global client base.

For more information, visit www.biovian.com

Press Contact:

Taru Värri, Marketing Manager at Biovian
taru.varri@biovian.com
+358 50 3650973

Note to editors: Images and additional information about Biovian and the facility expansion are available upon request.